Delivery Order SPE2DB24D3013-SPE2DB25FFNTF
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $4,785.59 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 12.5 mg/0.5 mL pens on July 18, 2025, with completion scheduled for July 21, 2025. This competitively awarded, firm fixed-price delivery order represents part of AmerisourceBergen's broader pharmaceutical supply operations supporting federal medical procurement needs. The company, headquartered in Conshohocken, Pennsylvania, serves as a...
- The Defense Logistics Agency awarded a $1,298.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on July 24, 2025, with an ultimate completion date of July 25, 2025. This is a non-set-aside contract, indicating open competition. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran healthcare systems. The...
- The Defense Logistics Agency awarded a $17,564.19 delivery order to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This competitively awarded, firm fixed-price contract includes no set-aside designation and specifies performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a small-value transaction within the company's...
- The Defense Logistics Agency awarded a $19,343.26 delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Zepbound (semaglutide) 10 mg/0.5 mL pens. This competitively awarded, firm fixed-price contract is classified as a non-set-aside procurement and requires completion by July 25, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the company maintains its corporate headquarters. This delivery order is issued...
- The Defense Logistics Agency awarded a $14,615.04 delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pen injections on July 18, 2025, with completion scheduled for July 21, 2025. This contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award through open competition. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order valued at $2,015.96 to AmerisourceBergen Drug Corp for Zepbound 5 mg/0.5 ml pen (semaglutide injection) on July 18, 2025, with an ultimate completion date of July 21, 2025. This is a firm fixed-price delivery order with no set-aside designation, awarded through open competition. The pharmaceutical product will be delivered to the place of performance in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $7,625.80 to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 10 mg/0.5 mL pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This firm fixed-price delivery order represents a non-competitive set-aside procurement and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider,...
- The Defense Logistics Agency (DLA) awarded a $5,778.56 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 2.5 mg/0.5 mL pens on July 18, 2025, with a completion date of July 21, 2025. This is a non-set-aside, competitively awarded contract for pharmaceutical supply to support federal medical procurement needs. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for military...
- The Defense Logistics Agency awarded a $5,318.93 firm fixed price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 7.5 mg/0.5 mL pens on July 25, 2025, with an ultimate completion date of July 28, 2025. This non-set-aside competitive award was issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion global pharmaceutical support vehicle running through December 2026. The place of performance is...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $50,732.31 to AmerisourceBergen Drug Corp for the supply of Zepbound (semaglutide) 5 mg/0.5 mL pen injections. This non-competitive, firm fixed-price delivery order was awarded on July 21, 2025, with an ultimate completion date of July 22, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger...
- SPE2DB24D3013Indefinite Delivery Contract
- SPE2DB24D3013-SPE2DB25FFNTFDelivery Order
The Defense Logistics Agency awarded a $1,871.51 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Zepbound (semaglutide) 5 mg/0.5 mL pens on July 28, 2025, with completion targeted for July 29, 2025. This non-competitive delivery order is issued against AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. The product will be delivered to AmerisourceBergen's distribution facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp serves as a major pharmaceutical distributor supporting federal medical procurement needs, particularly for military and veteran healthcare systems. This delivery order represents a routine pharmaceutical resupply transaction under the broader DLA Troop Support Medical prime vendor contract, which enables AmerisourceBergen to supply comprehensive pharmaceutical products and medical commodities to support Defense Health Agency and other government healthcare programs worldwide. The company's federal contract portfolio demonstrates extensive experience delivering specialty medications, brand-name and generic drugs, vaccines, and related medical supplies across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.9k | 7/28/25 |